

SUPPLEMENTARY MATERIALS

Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis

Katherine P. Liao¹, Chandrasekar Gopalakrishnan², Jinoos Yazdany³, Suraj Sarvode Mothi², Genevieve Gauthier⁴, Griffith Bell⁵, Arne Yndestad⁶, Milena Gianfrancesco⁵

¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA

²OMI, Inc., Boston, MA, USA

³Division of Rheumatology, School of Medicine, University of California, San Francisco, CA, USA

⁴Pfizer Canada ULC, Kirkland, QC, Canada

⁵Pfizer Inc, New York, NY, USA

⁶Pfizer Inc, Oslo, Norway

Correspondence to: Milena A. Gianfrancesco, Pfizer Inc, 66 Hudson Boulevard E, New York, NY, 10001, USA. Email: Milena.Gianfrancesco@pfizer.com

Supplementary Table 1 Demographics/clinical characteristics^a of TNFi-experienced patients with RA initiating treatment, before and after PS weighting

	Before propensity score weighting			After propensity score weighting			
				Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i	
	Tofacitinib (N = 1,472)	Abatacept (N = 1,433)	IL-6i (N = 1,023)	Tofacitinib (N = 1,472)	Abatacept (N = 1,433)	Tofacitinib (N = 1,472)	IL-6i (N = 1,023)
Age at index (years), mean (SD) [Std. Diff]	56.3 (12.3)	59.0 (13.1) [0.21]	59.0 (12.9) [0.21]	57.4 (12.4)	57.7 (13.0) [0.02]	57.1 (12.5)	57.2 (13.0) [0.01]
Female, n (%) [Std. Diff]	1,193 (81.0)	1,175 (82.0) [0.02]	815 (79.7) [-0.03]	1,232 (82.7)	1,174 (82.2) [-0.01]	1,237 (82.1)	828 (81.9) [0]
Observed RA disease duration ≥ 2 years, n (%) [Std. Diff]	933 (63.4)	877 (61.2) [-0.05]	687 (67.2) [0.08]	929 (62.3)	895 (62.7) [0.01]	977 (64.8)	646 (63.9) [-0.02]
Insurance, n (%) ^b [Std. Diff]							
Commercial	489 (33.2)	472 (32.9) [-0.01]	330 (32.3) [-0.02]	491 (32.9)	466 (32.6) [-0.01]	494 (32.7)	329 (32.6) [0]
Medicare	389 (26.4)	523 (36.5) [0.22]	395 (38.6) [0.26]	467 (31.3)	451 (31.6) [0]	478 (31.7)	320 (31.7) [0]
Medicaid	94 (6.4)	67 (4.7) [-0.07]	67 (6.5) [0.01]	88 (5.9)	89 (6.2) [0.01]	95 (6.3)	69 (6.9) [0.02]
Unknown	621 (42.2)	538 (37.5) [-0.09]	339 (33.1) [-0.19]	597 (40.0)	566 (39.6) [-0.01]	582 (38.6)	385 (38.1) [-0.01]
Census region, n (%) [Std. Diff]							
Northeast	229 (15.6)	180 (12.6) [-0.09]	137 (13.4) [-0.06]	200 (13.4)	194 (13.6) [0]	216 (14.3)	144 (14.2) [0]

Midwest	182 (12.4)	145 (10.1) [-0.07]	111 (10.9) [-0.05]	162 (10.9)	164 (11.5) [0.02]	164 (10.9)	110 (10.8) [0]
South	983 (66.8)	1,034 (72.2) [0.12]	699 (68.3) [0.03]	1,050 (70.5)	994 (69.6) [-0.02]	1,040 (69.0)	693 (68.6) [-0.01]
West	74 (5.0%)	74 (5.2) [0.01]	74 (7.2) [0.09]	76 (5.1%)	76 (5.4%) [0.01]	83 (5.5)	61 (6.1%) [0.02]
Unknown	4 (0.3)	0 [-0.07]	2 (0.2) [-0.02]	2 (0.1)	0 [-0.05]	4 (0.2)	3 (0.3) [0.01]
BMI (kg/m ²), mean (SD) ^c [Std. Diff]	30.7 (7.0)	30.8 (7.5) [0]	30.8 (7.5) [0.01]	30.7 (7.2)	30.9 (7.4) [0.03]	30.6 (7.2)	31.0 (7.3) [0.05]
Charlson comorbidity index, mean (SD) [Std. Diff]	1.9 (1.5)	2.0 (1.6) [0.09]	2.1 (1.8) [0.12]	2.0 (1.6)	2.0 (1.6) [-0.01]	2.0 (1.6)	2.0 (1.6) [0]
Comorbidities, n (%) [Std. Diff]							
Cardiovascular disease ^d	706 (48.0)	747 (52.1) [0.08]	532 (52.0) [0.08]	738 (49.5)	715 (50.1) [0.01]	739 (49.0)	497 (49.1) [0]
Atherosclerosis and peripheral arterial disease	97 (6.6)	113 (7.9) [0.05]	97 (9.5) [0.11]	107 (7.2)	96 (6.7) [-0.02]	107 (7.1)	80 (7.9) [0.03]
Coronary artery disease	83 (5.6)	109 (7.6) [0.08]	80 (7.8) [0.09]	93 (6.2)	99 (6.9) [0.03]	93 (6.2)	70 (6.9) [0.03]
Dyslipidemia	441 (30.0)	478 (33.4) [0.07]	348 (34.0) [0.09]	468 (31.4)	450 (31.5) [0]	475 (31.5)	316 (31.3) [0]
Hypertension	568 (38.6)	614 (42.8) [0.09]	449 (43.9) [0.11]	596 (40.0)	585 (40.9) [0.02]	593 (39.4)	413 (40.8) [0.03]
COPD	108 (7.3)	117 (8.2) [0.03]	107 (10.5) [0.11]	108 (7.3)	108 (7.6) [0.01]	119 (7.9)	84 (8.3) [0.02]

Fibromyalgia	296 (20.1)	273 (19.1) [-0.03]	216 (21.1) [0.02]	297 (19.9)	287 (20.1) [0]	314 (20.8)	209 (20.6) [0]
Malignancies	75 (5.1)	84 (5.9) [0.03]	61 (6.0) [0.04]	83 (5.6)	83 (5.8) [0.01]	84 (5.6)	57 (5.7) [0]
Osteoporosis	174 (11.8)	187 (13.0) [0.04]	145 (14.2) [0.07]	190 (12.7)	173 (12.1) [-0.02]	196 (13.0)	124 (12.3) [-0.02]
Type I diabetes	26 (1.8)	29 (2.0) [0.02]	21 (2.1) [0.02]	26 (1.7)	26 (1.8) [0.01]	27 (1.8)	19 (1.8) [0.01]
Type II diabetes	217 (14.7)	236 (16.5) [0.05]	167 (16.3) [0.04]	233 (15.6)	222 (15.5) [0]	236 (15.6)	156 (15.5) [0]
Sjogren's disease	109 (7.4)	93 (6.5) [-0.04]	68 (6.6) [-0.03]	117 (7.9)	102 (7.1) [-0.03]	125 (8.3)	77 (7.6) [-0.02]
Smoking status, n (%) ^c [Std. Diff]							
Ever smoking (current/former)	375 (25.5)	363 (25.3) [0]	261 (25.5) [0]	374 (25.1)	361 (25.3) [0.01]	371 (24.6)	251 (24.9) [0.01]
Unknown	214 (14.5)	206 (14.4) [0]	160 (15.6) [0.03]	210 (14.1)	207 (14.5) [0.01]	211 (14.0)	145 (14.3) [0.01]
CDAI, mean (SD) ^c [Std. Diff]	20.3 (12.6)	19.6 (11.8) [-0.06]	21.9 (12.7) [0.13]	20.3 (12.6)	19.9 (12.0) [-0.04]	20.9 (12.5)	21.0 (12.8) [0.01]
Categorical CDAI, n (%) ^c [Std. Diff]							
Remission: 0.0–2.8	87 (5.9)	62 (4.3) [-0.07]	42 (4.1) [-0.08]	76 (5.1)	74 (5.2) [0]	75 (5.0)	52 (5.1) [0.01]
Low activity: 2.9–10.0	247 (16.8)	267 (18.6) [0.05]	129 (12.6) [-0.12]	262 (17.6)	251 (17.6) [0]	226 (15.0)	155 (15.3) [0.01]
Moderate activity: 10.1–22.0	584 (39.7)	587 (41.0) [0.03]	420 (41.1) [0.03]	593 (39.8)	566 (39.6) [0]	608 (40.3)	409 (40.4) [0]

High activity: 22.1–76.0	554 (37.6)	517 (36.1)	432 (42.2)	560 (37.5)	537 (37.6)	599 (39.7)	396 (39.1)
		[-0.03]	[0.09]		[0]		[-0.01]
TJC, mean (SD) [Std. Diff]	6.7 (6.6)	6.2 (6.4)	7.0 (6.7)	6.7 (6.8)	6.4 (6.3)	6.9 (6.8)	6.7 (6.6)
		[-0.07]	[0.04]		[-0.06]		[-0.03]
SJC, mean (SD) [Std. Diff]	4.3 (4.7)	4.0 (4.5)	4.5 (5.0)	4.2 (4.7)	4.0 (4.5)	4.3 (4.9)	4.3 (5.0)
		[-0.07]	[0.06]		[-0.04]		[0]
Laboratory results, n (%) ^c [Std. Diff]							
RF							
Positive	139 (9.4)	142 (9.9)	120 (11.7)	137 (9.2)	133 (9.3)	152 (10.1)	102 (10.1)
		[0.02]	[0.07]		[0]		[0]
Negative	108 (7.3)	122 (8.5)	68 (6.6)	114 (7.6)	115 (8.1)	101 (6.7)	72 (7.2)
		[0.04]	[-0.03]		[0.02]		[0.02]
Unknown	1,225 (83.2)	1,169 (81.6)	835 (81.6)	1,239 (83.2)	1,180 (82.6)	1,254 (83.2)	837 (82.7)
		[-0.04]	[-0.04]		[-0.01]		[-0.01]
Anti-citrullinated peptide antibody							
Positive	144 (9.8)	170 (11.9)	115 (11.2)	150 (10.1)	147 (10.3)	157 (10.4)	100 (9.9)
		[0.07]	[0.05]		[0.01]		[-0.02]
Negative	273 (18.5)	245 (17.1)		273 (18.3)	262 (18.4)	269 (17.9)	177 (17.6)
		[-0.04]			[0]		[-0.01]
Unknown	1,055 (71.7)	1,018 (71.0)	735 (71.8)	1,068 (71.6)	1,019 (71.4)	1,082 (71.7)	734 (72.6)
		[-0.01]	[0]		[-0.01]		[0.02]
CRP, mg/L							
≥ 3	777 (52.8)	744 (51.9)	594 (58.1)	778 (52.2)	748 (52.4)	825 (54.7)	548 (54.2)
		[-0.02]	[0.11]		[0]		[-0.01]
< 3	435 (29.6)	421 (29.4)		448 (30.0)	422 (29.6)	444 (29.5)	296 (29.3)
		[0]			[-0.01]		[0]

Unknown	260 (17.7)	268 (18.7) [0.03]	151 (14.8) [-0.08]	264 (17.7)	258 (18.1) [0.01]	239 (15.8)	167 (16.5) [0.02]
Prior medication use (ever), n (%) [Std. Diff]							
csDMARDs ^f	1,271 (86.3)	1,228 (85.7) [-0.02]	877 (85.7) [-0.02]	1,285 (86.2)	1,231 (86.2) [0]	1,304 (86.5)	871 (86.2) [-0.01]
bDMARDs ^g	1,472 (100.0)	1,433 (100) [0]	1,023 (100) [0]	1,490 (100)	1,428 (100) [0]	1,508 (100)	1,011 (100) [0]
tsDMARDs ^h	58 (3.9)	173 (12.1) [0.30]	219 (21.4) [0.54]	159 (10.7)	120 (8.4) [-0.08]	210 (13.9)	117 (11.5) [-0.07]
Concomitant csDMARD use, n (%) [Std. Diff]	789 (53.6)	788 (55.0) [0.03]	544 (53.2) [-0.01]	793 (53.2)	784 (54.9) [0.03]	788 (52.2)	549 (54.3) [0.04]
Number of prior b/tsDMARDs, n (%) [Std. Diff]							
0	0	0 [0]	0 [0]	0	0 [0]	0 (0.0)	0 [0]
1	632 (42.9)	706 (49.3) [0.13]	337 (32.9) [-0.21]	664 (44.5)	653 (45.7) [0.02]	570 (37.8)	395 (39.1) [0.03]
2	498 (33.8)	459 (32.0) [-0.04]	355 (34.7) [0.02]	499 (33.5)	470 (32.9) [-0.01]	519 (34.4)	344 (34.0) [-0.01]
3	228 (15.5)	196 (13.7) [-0.05]	186 (18.2) [0.07]	225 (15.1)	207 (14.5) [-0.02]	250 (16.6)	172 (17.0) [0.01]
≥ 4	114 (7.7)	72 (5.0) [-0.11]	145 (14.2) [0.21]	102 (6.9)	99 (6.9) [0]	168 (11.2)	101 (10.0) [-0.04]
Corticosteroid use, n (%) ⁱ [Std. Diff]	1,036 (70.4)	1,006 (70.2) [0]	750 (73.3) [0.07]	1,033 (69.3)	998 (69.9) [0.01]	1,069 (70.9)	728 (72.0) [0.02]

All Std. Diff. are vs. tofacitinib. Sample sizes after PS weighting: tofacitinib $N = 1,490$, abatacept $N = 1,428$ (tofacitinib vs. abatacept); tofacitinib $N = 1,508$ and IL-6i

$N = 1,011$ (tofacitinib vs. IL-6i)

bdMARD biologic disease-modifying antirheumatic drug, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *COPD* chronic obstructive pulmonary disease, *CRP* C-reactive protein, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *IL-6i* interleukin-6 inhibitor, *N* total number of patients, *n* number of patients with characteristic, *pcJIA* polyarticular course juvenile idiopathic arthritis, *PS* propensity score, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *RF* rheumatoid factor, *SD* standard deviation, *SJC* swollen joint count, *Std. Diff* standardized difference, *TJC* tender joint count, *TNFi* tumor necrosis factor inhibitor, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug, *UC* ulcerative colitis

^aAssessed during the baseline period, defined as all available data prior to and including the index date (date of treatment initiation), unless otherwise stated. Patients diagnosed with concomitant indications for tofacitinib (PsA, UC, pcJIA) any time prior to index date were excluded (required at least 2 diagnosis codes at least 30 days apart)

^bInsurance categories are not mutually exclusive; total percentage may exceed 100%

^cFor BMI, smoking, and laboratory measures, the most recent value over the baseline period was used

^dCardiovascular disease includes atherosclerosis, coronary artery disease, dyslipidemia, hypertension, and peripheral arterial disease

^eMost recent value in the 45 days prior to and including the index date

^fcsDMARDs include auranofin, azathioprine, cyclophosphamide, cyclosporine, gold sodium thiomalate, hydroxychloroquine, leflunomide, methotrexate, minocycline, penicillamine, and sulfasalazine

^gbdMARDs include abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, and tocilizumab

^htsDMARDs include baricitinib, tofacitinib, and upadacitinib

ⁱIn the 6 months prior to and including the index date

Supplementary Table 2 Demographics/clinical characteristics^a of patients with RA initiating treatment, after PS weighting (overall population)

	Tofacitinib vs. TNFi		Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i	
	Tofacitinib (N = 3,681)	TNFi (N = 11,667)	Tofacitinib (N = 3,681)	Abatacept (N = 3,528)	Tofacitinib (N = 3,681)	IL-6 (N = 2,464)
Age at index (years), mean (SD) [Std. Diff]	58.3 (12.7)	58.2 (13.5) [-0.01]	59.3 (12.5)	59.4 (13.2) [0.01]	58.8 (12.6)	58.9 (13.1) [0.01]
Female, n (%) [Std. Diff]	3,036 (79.9)	9,239 (79.5) [-0.01]	3,085 (82.3)	2,885 (82.1) [0]	3,093 (81.6)	1,982 (81.4) [0]
Observed RA disease duration ≥ 2 years, n (%) [Std. Diff]	2,086 (54.9)	6,157 (52.9) [-0.04]	2,381 (63.5)	2,242 (63.8) [0.01]	2,530 (66.7)	1,626 (66.8) [0]
Insurance, n (%) ^b [Std. Diff]						
Commercial	1,176 (31.0)	3,656 (31.4) [0.01]	1,196 (31.9)	1,124 (32.0) [0]	1,180 (31.1)	758 (31.1) [0]
Medicare	1,303 (34.3)	3,866 (33.2) [-0.02]	1,387 (37.0)	1,324 (37.7) [0.01]	1,369 (36.1)	909 (37.3) [0.03]
Medicaid	244 (6.4)	656 (5.6) [-0.03]	222 (5.9)	222 (6.3) [0.02]	233 (6.1)	163 (6.7) [0.02]
Unknown	1,480 (39.0)	4,642 (39.9) [0.02]	1,403 (37.4)	1,294 (36.8) [-0.01]	1,427 (37.6)	884 (36.3) [-0.03]
Census region, n (%) [Std. Diff]						
Northeast	407 (10.7)	1,352 (11.6) [0.03]	449 (12.0)	433 (12.3) [0.01]	459 (12.1)	298 (12.2) [0]
Midwest	433 (11.4)	1,443 (12.4) [0.03]	423 (11.3)	408 (11.6) [0.01]	442 (11.7)	282 (11.6) [0]
South	2,702 (71.2)	8,084 (69.5) [-0.04]	2,658 (70.9)	2,458 (70.0) [-0.02]	2,654 (70.0)	1,697 (69.7) [-0.01]

West	254 (6.7%)	741 (6.4%) [-0.01]	215 (5.7)	208 (5.9%) [0.01]	232 (6.1)	155 (6.4%) [0.01]
Unknown	3 (0.1)	9 (0.1) [0]	6 (0.2)	6 (0.2) [0]	5 (0.1)	4 (0.2) [0.01]
BMI (kg/m ²), mean (SD) ^c [Std. Diff]	30.4 (7.2)	30.6 (7.3) [0.03]	30.5 (7.2)	30.7 (7.3) [0.03]	30.5 (7.2)	30.7 (7.2) [0.03]
Charlson comorbidity index, mean (SD) [Std. Diff]	2.0 (1.6)	1.9 (1.6) [-0.01]	2.1 (1.7)	2.1 (1.7) [-0.01]	2.1 (1.7)	2.1 (1.7) [0]
Comorbidities, n (%) [Std. Diff]						
Cardiovascular disease ^d	1,869 (49.2)	5,692 (48.9) [-0.01]	1,934 (51.6)	1,817 (51.7) [0]	1,931 (50.9)	1,241 (51.0) [0]
Atherosclerosis and peripheral arterial disease	299 (7.9)	924 (7.9) [0]	327 (8.7)	315 (9.0) [0.01]	324 (8.6)	228 (9.3) [0.03]
Coronary artery disease	272 (7.2)	802 (6.9) [-0.01]	289 (7.7)	297 (8.4) [0.03]	289 (7.6)	210 (8.6) [0.04]
Dyslipidemia	1,175 (30.9)	3,644 (31.3) [0.01]	1,229 (32.8)	1,158 (33.0) [0]	1,230 (32.4)	809 (33.2) [0.02]
Hypertension	1,547 (40.7)	4,704 (40.5) [-0.01]	1,599 (42.6)	1,493 (42.5) [0]	1,588 (41.9)	1,031 (42.3) [0.01]
COPD	286 (7.5)	899 (7.7) [0.01]	330 (8.8)	312 (8.9) [0]	343 (9.0)	228 (9.4) [0.01]
Fibromyalgia	606 (16.0)	1,887 (16.2) [0.01]	743 (19.8)	695 (19.8) [0]	772 (20.4)	506 (20.8) [0.01]
Malignancies	222 (5.8)	668 (5.7) [0]	248 (6.6)	240 (6.8) [0.01]	241 (6.4)	155 (6.4) [0]
Osteoporosis	489 (12.9)	1,370 (11.8) [-0.03]	537 (14.3)	490 (13.9) [-0.01]	558 (14.7)	347 (14.3) [-0.01]
Type I diabetes	55 (1.4)	178 (1.5) [0.01]	58 (1.5)	59 (1.7) [0.01]	61 (1.6)	41 (1.7) [0.01]

Type II diabetes	581 (15.3)	1,745 (15.0) [-0.01]	601 (16.0)	568 (16.2) [0]	595 (15.7)	387 (15.9) [0.01]
Sjogren's disease	291 (7.7)	805 (6.9) [-0.03]	335 (8.9)	288 (8.2) [-0.03]	322 (8.5)	196 (8.0) [-0.02]
Smoking status, n (%) ^c [Std. Diff]						
Ever smoking (current/former)	947 (24.9)	3,006 (25.8) [0.02]	980 (26.1)	935 (26.6) [0.01]	1,008 (26.6)	662 (27.2) [0.01]
Unknown	575 (15.1)	1,807 (15.5) [0.01]	537 (14.3)	517 (14.7) [0.01]	514 (13.6)	333 (13.7) [0]
CDAI, mean (SD) ^e [Std. Diff]	19.1 (13.0)	19.1 (12.3) [0]	19.8 (12.8)	19.5 (12.4) [-0.03]	20.4 (12.9)	20.2 (12.6) [-0.02]
Categorical CDAI, n (%) ^e [Std. Diff]						
Remission: 0.0–2.8	230 (6.1)	725 (6.2) [0.01]	205 (5.5)	199 (5.7) [0.01]	192 (5.1)	128 (5.2) [0.01]
Low activity: 2.9–10.0	821 (21.6)	2,304 (19.8) [-0.04]	732 (19.5)	686 (19.5) [0]	673 (17.8)	442 (18.1) [0.01]
Moderate activity: 10.1–22.0	1,492 (39.3)	4,604 (39.6) [0.01]	1,462 (39.0)	1,374 (39.1) [0]	1,494 (39.4)	952 (39.1) [-0.01]
High activity: 22.1–76.0	1,254 (33.0)	3,995 (34.4) [0.03]	1,352 (36.0)	1,256 (35.7) [-0.01]	1,433 (37.8)	914 (37.5) [-0.01]
TJC, mean (SD) [Std. Diff]	6.2 (6.7)	6.1 (6.5) [-0.02]	6.5 (6.8)	6.1 (6.3) [-0.06]	6.8 (6.9)	6.6 (6.5) [-0.02]
SJC, mean (SD) [Std. Diff]	4.0 (5.0)	4.0 (4.7) [-0.01]	4.2 (4.9)	4.0 (4.6) [-0.04]	4.3 (5.0)	4.2 (4.9) [-0.03]
Laboratory results, n (%) ^c [Std. Diff]						
RF						
Positive	413 (10.9)	1,229 (10.6) [-0.01]	378 (10.1)	354 (10.1) [0]	374 (9.9)	242 (10.0) [0]

Negative	274 (7.2)	826 (7.1) [0]	275 (7.3)	264 (7.5) [0.01]	255 (6.7)	162 (6.6) [0]
Unknown	3,110 (81.9)	9,573 (82.3) [0.01]	3,098 (82.6)	2,896 (82.4) [0]	3,163 (83.4)	2,031 (83.4) [0]
Anti-citrullinated peptide antibody						
Positive	393 (10.3)	1,230 (10.6) [0.01]	384 (10.2)	365 (10.4) [0.01]	365 (9.6)	232 (9.5) [0]
Negative	645 (17.0)	2,035 (17.5) [0.01]	632 (16.8)	585 (16.6) [-0.01]	628 (16.6)	400 (16.4) [0]
Unknown	2,760 (72.7)	8,363 (71.9) [-0.02]	2,735 (72.9)	2,564 (73.0) [0]	2,799 (73.8)	1,803 (74.0) [0.01]
CRP, mg/L						
≥ 3	1,846 (48.6)	5,762 (49.6) [0.02]	1,900 (50.7)	1,780 (50.7) [0]	1,987 (52.4)	1,258 (51.6) [-0.02]
< 3	947 (24.9)	2,888 (24.8) [0]	1,014 (27.0)	944 (26.9) [0]	1,005 (26.5)	653 (26.8) [0.01]
Unknown	1,004 (26.5)	2,978 (25.6) [-0.02]	836 (22.3)	790 (22.5) [0]	800 (21.1)	525 (21.6) [0.01]
Prior medication use (ever), n (%)						
[Std. Diff]						
csDMARDs ^f	3,115 (82.0)	9,742 (83.8) [0.05]	3,141 (83.7)	2,946 (83.8) [0]	3,165 (83.5)	2,024 (83.1) [-0.01]
bDMARDs ^g	1,691 (44.5)	5,097 (43.8) [-0.01]	2,504 (66.8)	2,332 (66.4) [-0.01]	2,796 (73.7)	1,781 (73.1) [-0.01]
tsDMARDs ^h	375 (9.9)	796 (6.8) [-0.11]	399 (10.6)	297 (8.5) [-0.07]	539 (14.2)	278 (11.4) [-0.08]
Concomitant csDMARD use, n (%)	2,180 (57.4)	7,332 (63.1) [0.12]	2,098 (55.9)	2,020 (57.5) [0.03]	2,061 (54.4)	1,381 (56.7) [0.05]
[Std. Diff]						

Number of prior b/tsDMARDs, n (%) [Std. Diff]						
0	2,006 (52.8)	6,296 (54.1) [0.03]	1,168 (31.1)	1,118 (31.8) [0.01]	933 (24.6)	615 (25.2) [0.01]
1	1,006 (26.5)	3,143 (27.0) [0.01]	1,257 (33.5)	1,199 (34.1) [0.01]	1,212 (32.0)	805 (33.1) [0.02]
2	459 (12.1)	1,301 (11.2) [-0.03]	780 (20.8)	715 (20.3) [-0.01]	888 (23.4)	563 (23.1) [-0.01]
3	199 (5.3)	543 (4.7) [-0.03]	370 (9.9)	330 (9.4) [-0.02]	464 (12.2)	287 (11.8) [-0.01]
≥ 4	127 (3.4)	346 (3.0) [-0.02]	175 (4.7)	153 (4.3) [-0.02]	295 (7.8)	166 (6.8) [-0.04]
Corticosteroid use, n (%) ⁱ [Std. Diff]	2,334 (61.5)	7,280 (62.6) [0.02]	2,461 (65.6)	2,307 (65.7) [0]	2,545 (67.1)	1,634 (67.1) [0]

All Std. Diff. are vs. tofacitinib. Sample sizes after PS weighting: tofacitinib $N = 3,798$, TNFi $N = 11,628$ (tofacitinib vs. TNFi); tofacitinib $N = 3,751$, abatacept $N = 3,514$ (tofacitinib vs. abatacept); tofacitinib $N = 3,792$ and IL-6i $N = 2,435$ (tofacitinib vs. IL-6i)

bDMARD biologic disease-modifying antirheumatic drug, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *COPD* chronic obstructive pulmonary disease, *CRP* C-reactive protein, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *IL-6* interleukin-6, *N* total number of patients, *n* number of patients with characteristic, *pcJIA* polyarticular course juvenile idiopathic arthritis, *PS* propensity score, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *RF* rheumatoid factor, *SD* standard deviation, *SJC* swollen joint count, *Std. Diff* standardized difference, *TJC* tender joint count, *TNFi* tumor necrosis factor inhibitor, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug, *UC* ulcerative colitis

^aAssessed during the baseline period, defined as all available data prior to and including the index date (date of treatment initiation), unless otherwise stated. Patients diagnosed with concomitant indications for tofacitinib (PsA, UC, pcJIA) any time prior to index date were excluded (required at least 2 diagnosis codes at least 30 days apart)

^bInsurance categories are not mutually exclusive; total percentage may exceed 100%

^cFor BMI, smoking, and laboratory measures, the most recent value over the baseline period was used

^dCardiovascular disease includes atherosclerosis, coronary artery disease, dyslipidemia, hypertension, and peripheral arterial disease

^eMost recent value in the 45 days prior to and including the index date

^fcsDMARDs include auranofin, azathioprine, cyclophosphamide, cyclosporine, gold sodium thiomalate, hydroxychloroquine, leflunomide, methotrexate, minocycline, penicillamine, and sulfasalazine

^gbDMARDs include abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, and tocilizumab

^htsDMARDs include baricitinib, tofacitinib, and upadacitinib

ⁱIn the 6 months prior to and including the index date

Supplementary Table 3 Censoring reasons before and after PS weighting for each cohort

	Before PS weighting						After PS weighting					
	Tofacitinib vs. TNFi		Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i		Tofacitinib vs. TNFi		Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i	
	Tofacitinib (N = 3,681)	TNFi (N = 11,667)	Tofacitinib (N = 3,681)	Abatacept (N = 3,528)	Tofacitinib (N = 3,681)	IL-6i (N = 2,464)	Tofacitinib (N = 3,681)	TNFi (N = 11,667)	Tofacitinib (N = 3,681)	Abatacept (N = 3,528)	Tofacitinib (N = 3,681)	IL-6i (N = 2,464)
Time to outcome event or censor at 6 months, days, mean (SD) [Std. Diff]	156.8 (74.9)	167.1 (68.4) [0.14]	158.4 (73.9)	162.9 (71.4) [0.06]	158.2 (74.2)	155.8 (74.4) [-0.03]	149.6 (79.5)	167.8 (68.1) [0.25]	154.0 (76.8)	164.5 (70.3) [0.14]	152.9 (78.1)	158.2 (73.3) [0.07]
Time to outcome event or censor at 12 months, days, mean (SD) [Std. Diff]	242.6 (150.0)	258.1 (140.7) [0.11]	245.5 (149.0)	250.9 (143.5) [0.04]	245.3 (149.3)	231.2 (144.7) [-0.10]	227.4 (154.2)	259.5 (140.4) [0.22]	235.3 (151.6)	255.6 (142.8) [0.14]	232.6 (152.9)	238.5 (144.4) [0.04]
CDAI observed in outcome assessment window, n (%) [Std. Diff]												
CDAI result at 6 months	2,160 (58.7)	6,455 (55.3) [-0.07]	2,160 (58.7)	2,104 (59.6) [0.02]	2,160 (58.7)	1,402 (56.9) [-0.04]	2,178 (57.3)	6,434 (55.3) [-0.04]	2,212 (59.0)	2,095 (59.6) [0.01]	2,237 (59.0)	1,390 (57.1) [-0.04]
CDAI result at 12 months	1,729 (47.0)	5,032 (43.1) [-0.08]	1,729 (47.0)	1,683 (47.7) [0.01]	1,729 (47.0)	1,111 (45.1) [-0.04]	1,683 (44.3)	5,065 (43.6) [-0.02]	1,717 (45.8)	1,665 (47.4) [0.03]	1,700 (44.8)	1,115 (45.8) [0.02]
Censoring reasons at 6 months, n (%) [Std. Diff]												
Treatment discontinuation	1,245 (33.8)	4,266 (36.6) [0.06]	1,376 (37.4)	1,332 (37.8) [0.01]	1,384 (37.6)	1,078 (43.8) [0.13]	1,388 (36.5)	4,225 (36.3) [0]	1,483 (39.5)	1,289 (36.7) [-0.06]	1,543 (40.7)	1,011 (41.5) [0.02]
Treatment switch	378 (10.3)	193 (1.7) [-0.37]	222 (6.0)	85 (2.4) [-0.18]	211 (5.7)	57 (2.3) [-0.17]	415 (10.9)	197 (1.7) [-0.39]	235 (6.3)	90 (2.6) [-0.18]	217 (5.7)	53 (2.2) [-0.18]
Lost to follow-up or end of study period	13 (0.4)	67 (0.6) [0.03]	13 (0.4)	12 (0.3) [0]	13 (0.4)	12 (0.5) [0.02]	32 (0.8)	59 (0.5) [-0.04]	23 (0.6)	9 (0.3) [-0.05]	32 (0.9)	9 (0.4) [-0.06]
End of assessment window	1,363 (37.0)	4,566 (39.1) [0.04]	1,380 (37.5)	1,336 (37.9) [0.01]	1,386 (37.7)	892 (36.2) [-0.03]	1,299 (34.2)	4,625 (39.8) [0.12]	1,344 (35.8)	1,356 (38.6) [0.06]	1,362 (35.9)	902 (37.0) [0.02]

Censoring reasons at 12 months, n (%) [Std. Diff]												
Treatment discontinuation	1,739 (47.2)	6,550 (56.1) [0.18]	1,898 (51.6)	1,984 (56.2) [0.09]	1,899 (51.6)	1,552 (63.0) [0.23]	1,905 (50.2)	6,479 (55.7) [0.11]	2,029 (54.1)	1,920 (54.6) [0.01]	2,086 (55.0)	1,477 (60.6) [0.11]
Treatment switch	475 (12.9)	283 (2.4) [-0.40]	288 (7.8)	117 (3.3) [-0.20]	291 (7.9)	86 (3.5) [-0.19]	517 (13.6)	286 (2.5) [-0.42]	297 (7.9)	122 (3.5) [-0.19]	296 (7.8)	84 (3.4) [-0.19]
Lost to follow-up or end of study period	21 (0.6)	105 (0.9) [0.04]	21 (0.6)	26 (0.7) [0.02]	21 (0.6)	19 (0.8) [0.02]	43 (1.1)	93 (0.8) [-0.04]	33 (0.9)	21 (0.6) [-0.03]	42 (1.1)	13 (0.5) [-0.06]
End of assessment window	990 (26.9)	3,047 (26.1) [-0.02]	1,006 (27.3)	897 (25.4) [-0.04]	1,004 (27.3)	541 (22.0) [-0.12]	894 (23.5)	3,115 (26.8) [0.07]	944 (25.2)	952 (27.1) [0.04]	938 (24.7)	573 (23.5) [-0.03]

All Std. Diff. are vs. tofacitinib. Sample sizes after PS weighting: tofacitinib $N=3,798$, TNFi $N=11,628$ (tofacitinib vs. TNFi); tofacitinib $N=3,751$, abatacept $N=3,514$ (tofacitinib vs. abatacept); tofacitinib $N=3,792$ and IL-6i $N=2,435$ (tofacitinib vs. IL-6i)

CDAI Clinical Disease Activity Index, *IL-6i* interleukin-6 inhibitor, N total number of patients, n number of patients with outcome, *PS* propensity score, *TNFi* tumor necrosis factor inhibitor, *SD* standard deviation, *Std. Diff* standardized difference

Supplementary Table 4 Censoring reasons before and after PS weighting for each cohort (TNFi-experienced patients)

	Before propensity score weighting				After propensity score weighting			
	Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i		Tofacitinib vs. abatacept		Tofacitinib vs. IL-6i	
	Tofacitinib (N = 1,472)	Abatacept (N = 1,433)	Tofacitinib (N = 1,472)	IL-6i (N = 1,023)	Tofacitinib (N = 1,472)	Abatacept (N = 1,433)	Tofacitinib (N = 1,472)	IL-6i (N = 1,023)
Time to outcome event or censor at 6 months, days, mean (SD) [Std. Diff]	157.2 (73.8)	158.4 (73.3) [0.02]	157.1 (74.0)	155.4 (73.9) [-0.02]	152.4 (76.3)	160.6 (71.7) [0.11]	152.0 (77.4)	158.0 (72.8) [0.08]
Time to outcome event or censor at 12 months, days, mean (SD) [Std. Diff]	241.7 (148.5)	240.8 (145.3) [-0.01]	241.9 (148.8)	229.5 (144.7) [-0.08]	231.9 (151.0)	245.6 (144.0) [0.09]	231.0 (152.4)	236.9 (144.2) [0.04]
CDAI observed in outcome assessment window, n (%) [Std. Diff]								
CDAI result at 6 months	879 (59.7)	838 (58.5) [-0.03]	879 (59.7)	567 (55.4) [-0.09]	896 (60.1)	846 (59.2) [-0.02]	906 (60.1)	570 (56.4) [-0.08]
CDAI result at 12 months	717 (48.7)	643 (44.9) [-0.08]	717 (48.7)	461 (45.1) [-0.07]	709 (47.5)	638 (44.7) [-0.06]	714 (47.4)	456 (45.1) [-0.04]
Censoring reasons at 6 months, n (%) [Std. Diff]								
Treatment discontinuation	567 (38.5)	600 (41.9) [0.07]	575 (39.1)	462 (45.2) [0.12]	605 (40.6)	578 (40.5) [0]	629 (41.7)	430 (42.5) [0.02]
Treatment switch	103 (7.0)	38 (2.7) [-0.20]	93 (6.3)	25 (2.4) [-0.19]	112 (7.5)	43 (3.0%) [-0.20]	104 (6.9)	24 (2.4) [-0.21]
Lost to follow-up or end of study period	2 (0.1)	5 (0.3) [0.04]	2 (0.1)	3 (0.3) [0.03]	3 (0.2)	4 (0.3) [0.01]	3 (0.2)	2 (0.2) [-0.01]
End of assessment window	532 (36.1)	513 (35.8) [-0.01]	535 (36.3)	373 (36.5) [0]	514 (34.5)	521 (36.4) [0.04]	529 (35.1)	376 (37.2) [0.04]

Censoring reasons at 12 months,
n (%) [Std. Diff]


Treatment discontinuation	764 (51.9)	855 (59.7) [0.16]	774 (52.6)	651 (63.6) [0.23]	810 (54.4)	828 (58.0) [0.07]	834 (55.3)	620 (61.3) [0.12]
Treatment switch	139 (9.4)	54 (3.8) [-0.23]	127 (8.6)	32 (3.1) [-0.24]	144 (9.7)	58 (4.0) [-0.23]	134 (8.9)	34 (3.4) [-0.23]
Lost to follow-up or end of study period	4 (0.3)	11 (0.8) [0.07]	4 (0.3)	8 (0.8) [0.07]	6 (0.4)	10 (0.7) [0.04]	6 (0.4)	5 (0.5) [0.02]
End of assessment window	376 (25.5%)	352 (24.6) [-0.02]	377 (25.6)	220 (21.5) [-0.10]	353 (23.7)	370 (25.9) [0.05]	359 (23.8)	228 (22.5) [-0.03]

All Std. Diff. are vs. tofacitinib. Sample sizes after propensity score weighting: tofacitinib $N = 1,490$, abatacept $N = 1,428$ (tofacitinib vs. abatacept); tofacitinib $N = 1,508$ and IL-6i $N = 1,011$ (tofacitinib vs. IL-6i)


CDAI Clinical Disease Activity Index, *IL-6i* interleukin-6 inhibitor, N total number of patients, n number of patients with outcome, PS propensity score, *TNFi* tumor necrosis factor inhibitor, SD standard deviation, *Std. Diff* standardized difference

Supplementary Figure 1 Tofacitinib vs. bDMARDs in achieving CDAI remission and LDA stratified by A) CDAI ≤ 10.0 and B) CDAI > 10.0 at baseline (after PS weighting)

A) CDAI ≤ 10 at baseline




B) CDAI > 10 at baseline




Baseline covariates used to estimate IPTW are described in the Methods. Sample sizes after PS weighting ($CDAI \leq 10$ at baseline): tofacitinib $N = 938$, TNFi $N = 3,031$ (tofacitinib vs. TNFi); tofacitinib $N = 914$, abatacept $N = 895$ (tofacitinib vs. abatacept); tofacitinib $N = 912$ and IL-6i $N = 500$ (tofacitinib vs. IL-6i). Sample sizes after propensity score weighting ($CDAI > 10$ at baseline): tofacitinib $N = 2,857$, TNFi $N = 8,596$ (tofacitinib vs. TNFi); tofacitinib $N = 2,832$, abatacept $N = 2,620$ (tofacitinib vs. abatacept); tofacitinib $N = 2,879$ and IL-6i $N = 1,937$ (tofacitinib vs. IL-6i). *bDMARD* biologic disease-modifying antirheumatic drug, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *HR* hazard ratio, *IL-6i* interleukin-6 inhibitor, *IPTW* inverse probability treatment weights, *IR* incidence rate, *LDA* low disease activity, N total number of patients, *PS* propensity score, *PY* patient year, *TNFi* tumor necrosis factor inhibitor

Supplementary Figure 2 Tofacitinib vs. bDMARDs in achieving CDAI remission and LDA
(overall population after PS weighting; sensitivity analyses)


A) On-treatment follow-up with IPTW and IPCW




B) On-treatment follow-up with outcome imputed to 1 for missing CDAI



C) On-treatment follow-up using eCDAI for missing CDAI



D) ITT follow-up using IPTW



Baseline covariates used to estimate IPTW are described in the Methods. Sample sizes after PS weighting

(IPTW and 6-month IPCW; CDAI remission/LDA and remission): tofacitinib $N = 2,018/2,062$,

TNFi $N = 6,885/7,160$ (tofacitinib vs. TNFi); tofacitinib $N = 2,064/2,113$, abatacept $N = 1,994/2,090$

(tofacitinib vs. abatacept); tofacitinib $N = 2,135/2,187$ and IL-6i $N = 1,248/1,305$ (tofacitinib vs. IL-6i).

Sample sizes after PS weighting (IPTW and 12-month IPCW; CDAI remission/LDA and remission):

tofacitinib $N = 1,435/1,469$, TNFi $N = 4,654/4,809$ (tofacitinib vs. TNFi); tofacitinib $N = 1,498/1,527$,

abatacept $N = 1,351/1,415$ (tofacitinib vs. abatacept); tofacitinib $N = 1,545/1,578$ and IL-6i $N = 778/805$

(tofacitinib vs. IL-6i). *bDMARD* biologic disease-modifying antirheumatic drug, *CDAI* Clinical Disease Activity

Index, *CI* confidence interval, *eCDAI* estimated Clinical Disease Activity Index, *HR* hazard ratio,


IL-6i interleukin-6 inhibitor, *IPCW* inverse probability of censoring weights, *IPTW* inverse probability treatment

weights, *IR* incidence rate, *ITT* intent-to-treat, *LDA* low disease activity, *N* total number of patients,

PS propensity score, *PY* patient year, *TNFi* tumor necrosis factor inhibitor


Supplementary Figure 3 Stratified analyses of tofacitinib vs. TNFi for CDAI LDA

(overall population)



Sample sizes after PS weighting: tofacitinib $N = 3,798$, TNFi $N = 11,628$ (tofacitinib vs. TNFi). ^aCRP was unknown in 833 (22.6%; tofacitinib) and 3,071 (26.3%; TNFi) patients. ^bSmoking status was unknown in 538 (14.6%; tofacitinib) and 1,832 (15.7%; TNFi) patients. *bDMARD* biologic disease-modifying antirheumatic drug, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *TNFi* tumor necrosis factor inhibitor, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug


Supplementary Figure 4 Stratified analyses of tofacitinib vs. abatacept for CDAI LDA (overall population)



Sample sizes after PS weighting: tofacitinib $N = 3,751$, abatacept $N = 3,514$ (tofacitinib vs. abatacept). ^aCRP was unknown in 833 (22.6%; tofacitinib) and 772 (21.9%; abatacept) patients. ^bSmoking status was unknown in 538 (14.6%; tofacitinib) and 523 (14.8%; abatacept) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug


Supplementary Figure 5 Stratified analyses of tofacitinib vs. IL-6i for CDAI LDA

(overall population)




Sample sizes after PS weighting: tofacitinib $N = 3,792$ and IL-6i $N = 2,435$ (tofacitinib vs. IL-6i). ^aCRP was unknown in 833 (22.6%; tofacitinib) and 486 (19.7%; IL-6i) patients. ^bSmoking status was unknown in 538 (14.6%; tofacitinib) and 338 (13.7%; IL-6i) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *IL-6i* interleukin 6 inhibitors, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 6 Stratified analyses of tofacitinib vs. TNFi for CDAI remission in patients with CDAI > 10 at baseline




Sample sizes after PS weighting: tofacitinib $N = 2,857$, TNFi $N = 8,596$ (tofacitinib vs. TNFi). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 2,085 (24.2%; TNFi) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 1,359 (15.8%; TNFi) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *TNFi* tumor necrosis factor inhibitor, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 7 Stratified analyses of tofacitinib vs. TNFi for CDAI LDA in patients with CDAI > 10 at baseline




Sample sizes after PS weighting: tofacitinib $N = 2,857$, TNFi $N = 8,596$ (tofacitinib vs. TNFi). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 2,085 (24.2%; TNFi) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 1,359 (15.8%; TNFi) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *TNFi* tumor necrosis factor inhibitor, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 8 Stratified analyses of tofacitinib vs. abatacept for CDAI remission in patients with CDAI > 10 at baseline




Sample sizes after PS weighting: tofacitinib $N = 2,832$, abatacept $N = 2,620$ (tofacitinib vs. abatacept). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 550 (20.9%; abatacept) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 370 (14.1%; abatacept) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 9 Stratified analyses of tofacitinib vs. abatacept for CDAI LDA in patients with CDAI > 10 at baseline




Sample sizes after PS weighting: tofacitinib $N = 2,832$, abatacept $N = 2,620$ (tofacitinib vs. abatacept). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 550 (20.9%; abatacept) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 370 (14.1%; abatacept) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 10 Stratified analyses of tofacitinib vs. IL-6i for CDAI remission in patients with CDAI > 10 at baseline



Sample sizes after PS weighting: tofacitinib $N = 2,879$ and IL-6i $N = 1,937$ (tofacitinib vs. IL-6i). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 359 (18.3%; IL-6i) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 260 (13.2%; IL-6i) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *IL-6i* interleukin 6 inhibitors, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug

Supplementary Figure 11 Stratified analyses of tofacitinib vs. IL-6i for CDAI LDA in patients with CDAI > 10 at baseline



Sample sizes after PS weighting: tofacitinib $N = 2,879$ and IL-6i $N = 1,937$ (tofacitinib vs. IL-6i). ^aCRP was unknown in 601 (21.7%; tofacitinib) and 359 (18.3%; IL-6i) patients. ^bSmoking status was unknown in 396 (14.3%; tofacitinib) and 260 (13.2%; IL-6i) patients. *bDMARD* biologic disease-modifying antirheumatic drugs, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CI* confidence interval, *CRP* C-reactive protein, *HR* hazard ratio, *IL-6i* interleukin 6 inhibitors, *LDA* low disease activity, *N* total number of patients, *n* number of patients with characteristic, *PS* propensity score, *RA* rheumatoid arthritis, *tsDMARD* targeted synthetic disease-modifying antirheumatic drug